Wegovy dose levels chart: what the UK schedule actually looks like

The myth: you can pick your dose from a chart and work up at your own pace

This is probably the most common misconception about Wegovy, and it's understandable. When people see a dose table showing 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg neatly laid out, it can look like a DIY ladder, climb as fast as you like. It isn't. Every step in the schedule is a prescriber's decision, made after checking that the previous dose has been tolerated well enough to move on.

Semaglutide causes gastrointestinal side effects (nausea especially, along with constipation, loose stools, reflux and fatigue) that are nearly always more pronounced when a dose increases. The titration schedule exists precisely to give your body time to adjust. Rushing it does not produce faster weight loss; it almost always produces worse nausea and a higher chance of stopping treatment early. The NHS semaglutide medicines page sets this out clearly: dose increases should follow clinical guidance, not impatience.

At a private clinic like nume, a GPhC-registered Independent Prescriber reviews your case before every dose change. That review exists to protect you, not to slow you down. If you're tolerating 1.0 mg well after four weeks and your weight progress supports moving up, a clinician can confirm that and proceed.

The Wegovy injection schedule: what each dose level is doing

The full UK injection schedule approved by the MHRA runs as follows: 0.25 mg for the first four weeks, 0.5 mg for weeks five to eight, 1.0 mg for weeks nine to twelve, 1.7 mg for weeks thirteen to sixteen, and then 2.4 mg as the original maintenance dose from week seventeen onwards. Your prescriber may keep you at any step longer if that's clinically appropriate.

The doses within the Wegovy injection range are not interchangeable by strength, the pens are manufactured at each specific dose and cannot be adjusted. If you are on 1.0 mg, you use a 1.0 mg pen. The pen for the next step is only prescribed when the step is clinically confirmed.

The higher 7.2 mg maintenance option, now approved by the MHRA and available as a dedicated single-dose pen, means the schedule can extend further for eligible patients. Trials at 7.2 mg reported average weight loss of around 20.7% over 72 weeks, approaching the results seen with tirzepatide at its highest dose in head-to-head evidence. Whether 7.2 mg is appropriate for you is a conversation for your prescriber, and reviewing the Wegovy dose chart before that conversation can help you understand where each step sits in the full sequence. The details of Wegovy's mg levels and how they compare are also worth reading.

One practical note on timing: if you're planning treatment around a holiday, a bank holiday week or a period where you'd struggle to keep to a consistent once-weekly day, mention that at the outset. Prescribers at our clinical team field this kind of question regularly, and the answer is almost always straightforward to plan around.

The 7.2 mg update and the oral Wegovy schedule: two things to keep separate

Since the MHRA approved the single-dose 7.2 mg pen in April 2026, some people reading dose charts online have encountered conflicting information, older articles show 2.4 mg as the ceiling, newer ones reference 7.2 mg. Both are accurate for different points in time. As of mid-2026, the licensed injection schedule tops out at 7.2 mg, and the dedicated pen simplifies what had previously required three separate 2.4 mg injections in a single week.

The oral Wegovy tablet schedule is entirely separate. Approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK, it uses a once-daily tablet with doses of 1.5 mg, 4 mg, 9 mg and 25 mg. These numbers look lower than the injection doses, but that's a consequence of different absorption, oral semaglutide is combined with an absorption enhancer and taken first thing in the morning on an empty stomach, with a sip of plain water, at least 30 minutes before any food or other medicines. A full comparison of Wegovy's dosage levels across both forms explains the distinction in more detail.

Do not attempt to cross-reference injection doses with tablet doses or treat them as equivalent, they aren't. Patients established on 2.4 mg weekly injection may be able to transition to the 25 mg tablet, but only under clinical supervision.

What the dose chart can't tell you: eligibility and clinical fit

A dose chart tells you what steps exist. It cannot tell you which step you'll start at, how quickly you'll progress, or whether Wegovy is the right medicine for you at all. That depends on your BMI, any existing conditions, other medicines you take and a range of clinical factors assessed at consultation. The licensed starting point for most adults is 0.25 mg, but prescribers can make individual decisions.

For context on cost alongside the clinical picture, the Wegovy cost page covers what private treatment typically involves. The NICE appraisal for semaglutide injection is TA875, which sets out NHS eligibility criteria, useful background even if you're pursuing a private route.

If you want a prescriber to walk through the schedule with you in the context of your specific situation, starting a free consultation is the most direct way to do that. Our prescribers can also answer questions about what the dosage levels for Wegovy mean in practice for someone at your stage.